Based on the integration of unbiased big data analyses, mass spectrometry and experimental validation including preclinical models, we identified the impact of the USP10/B7‐H4 proteolytic axis in orchestrating tumor immunogenicity and the therapeutic efficacy of ADCs. Here, VTCN1 is linked to neoplasm.